Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Clarity Pharmaceuticals Ltd. ( (AU:CU6) ) has provided an update.
Clarity Pharmaceuticals Ltd has notified the market of the cessation of 419,578 options (ASX code CU6AAM) that were due to expire on various dates at various exercise prices. The options lapsed on 31 December 2025 because the conditions attached to these conditional rights were not satisfied or had become incapable of being satisfied, resulting in a reduction of potential future dilution for existing shareholders and a modest simplification of the company’s capital structure.
The most recent analyst rating on (AU:CU6) stock is a Hold with a A$3.50 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.
More about Clarity Pharmaceuticals Ltd.
Clarity Pharmaceuticals Ltd is an ASX-listed company in the pharmaceuticals and biotechnology sector, focused on developing medical products and technologies. The company’s securities trade under the ASX issuer code CU6, reflecting its participation in public capital markets to fund and support its operations and growth initiatives.
Average Trading Volume: 2,539,212
Technical Sentiment Signal: Buy
Current Market Cap: A$1.43B
See more insights into CU6 stock on TipRanks’ Stock Analysis page.